MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2023.04.033

Медицинская библиотека · Journal of hepatology · 2023

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Andrade Raúl J, Aithal Guruprasad P, de Boer Ynto S, Liberal Rodrigo, Gerbes Alexander, Regev Arie, Terziroli Beretta-Piccoli Benedetta, Schramm Christoph, Kleiner David E, De Martin Eleonora, Kullak-Ublick Gerd A, Stirnimann Guido, Devarbhavi Harshad, Vierling John M, Manns Michael P, Sebode Marcial, Londoño Maria Carlota, Avigan Mark, Robles-Diaz Mercedes, García-Cortes Miren, Atallah Edmond, Heneghan Michael, Chalasani Naga, Trivedi Palak J, Hayashi Paul H, Taubert Richard, Fontana Robert J, Weber Sabine, Oo Ye Htun, Zen Yoh, Licata Anna, Lucena M Isabel, Mieli-Vergani Giorgina, Vergani Diego, Björnsson Einar S, IAIHG and EASL DHILI Consortium

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition.

Для цитирования: Andrade Raúl J, Aithal Guruprasad P, de Boer Ynto S, Liberal Rodrigo, Gerbes Alexander, Regev Arie, Terziroli Beretta-Piccoli Benedetta, Schramm Christoph, Kleiner David E, De Martin Eleonora, Kullak-Ublick Gerd A, Stirnimann Guido, Devarbhavi Harshad, Vierling John M, Manns Michael P, Sebode Marcial, Londoño Maria Carlota, Avigan Mark, Robles-Diaz Mercedes, García-Cortes Miren, Atallah Edmond, Heneghan Michael, Chalasani Naga, Trivedi Palak J, Hayashi Paul H, Taubert Richard, Fontana Robert J, Weber Sabine, Oo Ye Htun, Zen Yoh, Licata Anna, Lucena M Isabel, Mieli-Vergani Giorgina, Vergani Diego, Björnsson Einar S, IAIHG and EASL DHILI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.. Journal of hepatology. 2023. DOI: 10.1016/j.jhep.2023.04.033.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.